Background: COVID-19 typically starts as a mild illness that progresses over several days. Most treatment interventions for COVID-19 are focused on hospitalized patients who have progressed past this mild illness. Monoclonal antibodies have been heavily touted in this role for ...
Update: This article was removed from the Lancet server on February 19th, 2021 (Link) Background: Vitamin D deficiency is common amongst critically ill patients and there has been ample speculation about a possible role for supplementation (with calcifediol) in the ...
Background: Science by press release. Not the way any of us would choose to operate but, the COVID pandemic has made this a reality. It’s vital that we understand that while pharmaceutical companies have a responsibility to release this information, ...
Background: Publication of the RECOVERY trial results on Dexamethasone were game changing – the drug had a clear reduction in mortality in patients requiring oxygen. Since then, we have had little to celebrate in terms of therapeutics in those with ...
Background: One of the many massive challenges of the COVID19 pandemic has been the lack of targeted therapeutics. Extensive efforts have been invested into research with only glimmers of benefit for most drugs. The exception to this has been dexamethasone ...
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
